Last reviewed · How we verify
olopatadine (OLO)
Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses.
Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses. Used for Allergic conjunctivitis, Allergic rhinitis.
At a glance
| Generic name | olopatadine (OLO) |
|---|---|
| Also known as | Olopatadine 0.2% ophthalmic solution |
| Sponsor | University of Chicago |
| Drug class | Selective H1-receptor antagonist / mast cell stabilizer |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy / Immunology |
| Phase | FDA-approved |
Mechanism of action
Olopatadine works by competitively antagonizing H1 histamine receptors on target tissues, preventing histamine-induced allergic symptoms. Additionally, it stabilizes mast cells, reducing the release of inflammatory mediators. This dual mechanism makes it effective for allergic conditions, particularly allergic conjunctivitis and allergic rhinitis.
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
Common side effects
- Headache
- Ocular irritation (for ophthalmic formulation)
- Somnolence
- Bitter taste (for nasal formulation)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- olopatadine (OLO) CI brief — competitive landscape report
- olopatadine (OLO) updates RSS · CI watch RSS
- University of Chicago portfolio CI